FDA: Post-Approval Trial Of Fast-Tracked Myeloma Drug Shows Increased Death Risk
SILVER SPRING, Md. — The Food and Drug Administration on July 28 told patients and health care professionals that post-approval clinical trial results show an increased risk of death associated with...To view the full article, register now.
Already a subscriber? Click here to view full article